Myeloma

The Food and Drug Administration granted a priority review to belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma.

A multiple myeloma expert helps newly diagnosed patients understand the standard of care for their disease.

Patients with multiple myeloma have a lot to look forward to in the treatment space thanks to precision medicine, but one treatment option alone will not cure the disease.

At the 2019 CURE® Educated Patient® Summit on Multiple Myeloma patient advocate and 10-year survivor Terry White had the chance to share advice on handling a cancer diagnosis.

Naturally, newly diagnosed patients with multiple myeloma have a lot of questions for their physicians. Dr. Joshua Richter had the time to discuss some of them.

At CURE’s Educated Patient Summit on Multiple Myeloma Dr. Shebli Atrash had the chance to further discuss with CURE what questions he addresses most when patients with multiple myeloma undergo diagnostic testing.

At CURE’s Educated Patient Summit on Multiple Myeloma, Dr. Barry Paul discussed the role of minimal residual disease measurement and how it may be used in the future to determine treatment options for patients with myeloma.

Dr. Cesar Rodriguez offers a message of hope and self-determination for patients with multiple myeloma.

Expanding a combination from two drugs to three may lengthen the time until disease progression for patients with relapsed or refractory multiple myeloma.

A dual-targeted chimeric antigen receptor-T cell therapy showed a more than 90% overall response rate in patients with relapsed or refractory disease.

JNJ-4528 showed deep responses and proved to be safe in patients with multiple myeloma, according to CARTITUDE-1 study findings.

As patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

Meet four patients with multiple myeloma who have found hope and improved quality of life by participating in endurance events.

From new data released about CRISPR technology’s safety to Will Smith sharing his colonoscopy with the world, here’s what is making headlines in the cancer space this week.

College football anchor Rod Gilmore uses his voice to help raise awareness following a multiple myeloma diagnosis.

For Blood Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.

The four-drug regimen of Darzalex in combination with Velcade, Thalomid and dexamethasone has been approved for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant.

Here’s a look at what’s inside our 2019 Hematology special issue.

After learning to walk again following a life-changing multiple myeloma diagnosis, Richard Bell takes on Mount Washington.

Many patients with blood cancers may be candidates for autologous or allogeneic transplant.

Receiving supportive care can help ease symptoms of cancer and its treatment, improving quality of life for patients. But many with multiple myeloma are missing out on aspects of this type of care, according to study findings published in Cancer.

New technologies boost safety for patients with cancer who need donated blood.

Newer treatments for multiple myeloma come with an increased risk for thrombosis, but researchers discovered five factors that could help prevent the side effect.

CURE spoke with Ryan Anthony, a Dallas Symphony trumpet player, about how his passion for music led to his myeloma diagnosis and the start of his foundation CancerBlows.

From an FDA warning to real-life superheroes, here’s what is making headlines in the cancer space this week.

From today’s top performers and athletes to medical aid in dying, here’s what is making headlines in the cancer space this week.

Researchers examined what goes into treatment decision-making for patients with multiple myeloma.

The use of Darzalex in combination with Revlimid, Velcade and Ozurdex demonstrated a higher percentage of stringent complete responses among transplant eligible, newly diagnosed patients with multiple myeloma.

From today’s top performers and athletes to life-threatening social media disinformation, here’s what is making headlines in the cancer space this week.